07.07.21
Bioiberica, a global ingredients supplier specializing in both pharmaceutical and nutraceutical industries, announced that it is launching a new brand identity for its healthcare ingredients portfolio, which is focused on the joint health and mobility markets.
The rebranding initiative is part of a long-term strategy, which aims to set a platform for the company’s future growth and to support its customers and partners in the development of market-leading solutions to consumers’ present needs.
“At Bioiberica, everything we do is driven by an unstoppable desire to improve people’s health and wellbeing,” Jaume Reguant, director of healthcare at Bioiberica, said. “Faced with some of the most significant healthcare challenges of our time, we are embracing the need for solutions that go the extra mile. As we continue to evolve as a business, we are redefining the identity of our branded ingredients to better reflect the needs of the market. For our customers and partners, this means remaining at the forefront of innovation, with access to the latest science and ingredients in the healthcare space. The rebrand gives customers a suite of well-defined products, made more accessible and identifiable with a clearer brand architecture.”
The rebrand will comprise a renaming of Bioiberica's native (undenatured) type II collagen Collavant n2 (previously b-2cool) and the addition of Tendaxion, a new brand for its tendon health ingredient. These products will join Mobilee, a patented hyaluronic acid matrix ingredient, and CSbioactive, a chondroitin sulfate ingredient, in order to create a consolidated portfolio of clinically-backed products for the mobility market.
“Our initial move has been to refocus our mobility ingredients, but this is just the first step of many to offer a more comprehensive portfolio of solutions to our customers,” Reguant said. “We are constantly investing in our products – the science behind them, our understanding of the target market, and how they should be positioned to help our customers grow their business with truly innovative products. Our newly launched brand strategy for our healthcare-oriented ingredients is designed to deliver enhanced co-collaboration opportunities and a stronger foundation on which to build and market products, providing greater potential for growth in new areas – not just for Bioiberica, but for our partners, too.”
The rebranding initiative is part of a long-term strategy, which aims to set a platform for the company’s future growth and to support its customers and partners in the development of market-leading solutions to consumers’ present needs.
“At Bioiberica, everything we do is driven by an unstoppable desire to improve people’s health and wellbeing,” Jaume Reguant, director of healthcare at Bioiberica, said. “Faced with some of the most significant healthcare challenges of our time, we are embracing the need for solutions that go the extra mile. As we continue to evolve as a business, we are redefining the identity of our branded ingredients to better reflect the needs of the market. For our customers and partners, this means remaining at the forefront of innovation, with access to the latest science and ingredients in the healthcare space. The rebrand gives customers a suite of well-defined products, made more accessible and identifiable with a clearer brand architecture.”
The rebrand will comprise a renaming of Bioiberica's native (undenatured) type II collagen Collavant n2 (previously b-2cool) and the addition of Tendaxion, a new brand for its tendon health ingredient. These products will join Mobilee, a patented hyaluronic acid matrix ingredient, and CSbioactive, a chondroitin sulfate ingredient, in order to create a consolidated portfolio of clinically-backed products for the mobility market.
“Our initial move has been to refocus our mobility ingredients, but this is just the first step of many to offer a more comprehensive portfolio of solutions to our customers,” Reguant said. “We are constantly investing in our products – the science behind them, our understanding of the target market, and how they should be positioned to help our customers grow their business with truly innovative products. Our newly launched brand strategy for our healthcare-oriented ingredients is designed to deliver enhanced co-collaboration opportunities and a stronger foundation on which to build and market products, providing greater potential for growth in new areas – not just for Bioiberica, but for our partners, too.”
